Post Profile






PharmaMar shows new clinical data on Yondelis® and lurbinectedin at ESMO 2016

(Pharmamar) During this congress, PharmaMar will inform in an oral session the results of its Phase II clinical trial with lurbinectedin in patients with BRCA 1/2 metastatic breast cancer.A prospective randomized phase III comparing trabectedin versus the best supportive care in patients with pretreated advanced soft tissue sarcoma(T-SAR trial) will be presented in an oral session by the French Sarcoma Group.
read more

share

Related Posts


PharmaMar announces positive results from its Phase 2 study with PM1183 in BRCA 1/2 MBC

Health : EurekAlert: Health

(Pharmamar) The data was presented at an oral session at the European Society of Medical Oncology.The study meets its primary objective obtaining an overall response rate (ORR) in 41 percent of the patients. In the BRCA 2 subgroup, ...

Positive Results From Phase 2 Clinical Study Of NKTR-102 In Metastatic Breast Cancer Presented In Oral Session At The ASCO 2011 Symposium

Health : Medical News Today

Nektar Therapeutics (Nasdaq: NKTR) announced that positive results from the company's Phase 2 clinical study of NKTR-102 in patients with metastatic breast cancer were presented at the ASCO 2011 Breast Cancer Symposium in San Franci...

Phase III Trial Results For 2nd Line Treatment Of Metastatic Colorectal Cancer To Be Presented At ESMO 13th World Congress On Gastrointestinal Cancer

Health : Medical News Today

Results of a large, multi-national phase III trial for second-line treatment of metastatic colorectal cancer will be presented for the first time at the ESMO 13th World Congress on Gastrointestinal Cancer, beginning June 22 2011 in ...

Study Of Yondelis(R) In Ovarian Cancer Shows Significant Prolongation In Progression Free Survival

Health : Medical News Today

Positive final results of the Phase III randomized pivotal study of Yondelis® in ovarian cancer were presented during the Presidential Symposium at the ESMO congress in Stockholm. ESMO selects clinical studies that may result in a c...

PharmaMar completes the patient recruitment for the Phase 3 pivotal study with PM1183

Health : EurekAlert: Health

(Pharmamar) PharmaMar announces today that the patient recruitment for the randomized and pivotal Phase III 'CORAIL' study with lurbinectedin (PM1183), for the treatment of platinum-resistant ovarian cancer, has been successfully co...

Comments


Copyright © 2016 Regator, LLC